Autoimmunity as a trigger for structural bone damage in rheumatoid arthritis

Modern Rheumatology

Volumn 27, Issue 2, 2017, Pages 193-197

  Schett, Georg ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Autoantibodies; autoimmunity; bone erosion; osteoporosis; rheumatoid arthritis

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR; VIMENTIN;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; BONE EROSION; BONE INJURY; BONE REMODELING; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; HUMAN; INFLAMMATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; BONE; IMMUNOLOGY; PATHOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNITY; BONE AND BONES; BONE RESORPTION; HUMANS; RHEUMATOID FACTOR;

EID: 85008694188     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2016.1265907     Document Type: Review

References (51)

1. Takayanagi H., Osteoimmunology:shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7:292–304.
2. Schett G, Gravallese E., Bone erosion in rheumatoid arthritis:mechanisms, diagnosis and treatment. Nat Rev Rheumatol. 2012;8:656–64.
3. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL., TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481–8.
4. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145:3297–303.
5. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103:1345–52.
6. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL., IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282–90.
7. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–63.
8. Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24:1572–85.
9. Shaw AT, Maeda Y, Gravallese EM., IL-17A deficiency promotes periosteal bone formation in a model of inflammatory arthritis. Arthritis Res Ther. 2016;18:104. doi:10.1186/s13075-016-0998-x.
10. Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, et al. Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med. 2016;8:330-7.
11. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43:250–8.
12. Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA., Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol. 2000;192:97–104.
13. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259–69.
14. Nakano K, Okada Y, Saito K, Tanaka Y., Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum. 2004;50:2450–8.
15. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis:a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309.
16. Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2010;62:569–74.
17. Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis:a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE) - a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75:983–90.
18. Schett G, Stach C, Zwerina J, Voll R, Manger B., How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;5:2936–48.
19. McInnes IB, Schett G., Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42.
20. Bozec A, Zaiss MM, Kagwiria R, Voll R, Rauh M, Chen Z, et al. T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med. 2014;6:235–60.
21. de Rooy DP, Kalvesten J, Huizinga TW, van der Helm-van Mil AH., Loss of metacarpal bone density predicts RA development in recent-onset arthritis. Rheumatology (Oxford). 2012;51:1037–41.
22. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1508–12.
23. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis:a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380–6.
24. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741–9.
25. Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard S, et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin:results from a 10-year prospective study. Ann Rheum Dis. 2010;69:345–51.
26. Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, Ronnelid J., Antibodies against citrullinated vimentin in rheumatoid arthritis:higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008;58:36–45.
27. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. 2015;74:2151–6.
28. Kocijan R, Finzel S, Englbrecht M, Engelke K, Rech J, Schett G., Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity. Ann Rheum Dis. 2014;73:2022–8.
29. Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73:854–60.
30. van Schaardenburg D, Nielen MM, Lems WF, Twisk JW, Reesink HW, van de Stadt RJ, et al. Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis. 2011;70:1173–4.
31. Simon D, Kleyer A, Stemmler F, Simon C, Berlin A, Hueber AJ, et al. Age- and sex-dependent changes of intra-articular cortical and trabecular bone structure and the effects of rheumatoid arthritis. J Bone Miner Res. 2016. [Epub ahead of print]. doi:10.1002/jbmr.3025.
32. Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL., Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2002;61:1007–11.
33. Stewart A, Mackenzie LM, Black AJ, Reid DM., Predicting erosive disease in rheumatoid arthritis. A longitudinal study of changes in bone density using digital X-ray radiogrammetry:a pilot study. Rheumatology (Oxford). 2004;43:1561–4.
34. Röben P, Barkmann R, Ullrich S, Gause A, Heller M, Glüer CC., Assessment of phalangeal bone loss in patients with rheumatoid arthritis by quantitative ultrasound. Ann Rheum Dis. 2001;60(7):670–7.
35. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA., Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004;50:36–42.
36. Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients–a longitudinal analysis. Sem Arth Rheum. 2016. [Epub ahead of print]. doi:10.1016/j.semarthrit.2016.09.011.
37. Grevers LC, de Vries TJ, Everts V, Verbeek JS, van den Berg WB, van Lent PL. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells. Ann Rheum Dis. 2013;72:278–85.
38. Seeling M, Hillenhoff U, David JP, Schett G, Tuckermann J, Lux A, Nimmerjahn F. Inflammatory monocytes and Fc-gamma receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proc Nat Acad Sci USA. 2013;110:10729–34.
39. Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, et al. Immune complexes regulate bone metabolism through FcRγ signalling. Nat Commun. 2015;6:6637. doi:10.1038/ncomms7637.
40. Harre U, Lang SC, Pfeifle R, Rombouts Y, Fruhbeisser S, Amara K, et al. Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun. 2015;6:6651. doi:10.1038/ncomms7651.
41. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428:758–63.
42. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320:373–6.
43. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV., General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA. 2013;110:9868–72.
44. Pfeifle R, Rothe T, Scherer HU, Culemann S, Harre U, Ackermann J, et al. The IL-23/Th17 axis unlocks autoantibody activity and times onset of autoimmune disease. Nat Immunol. 2016. [Epub ahead of print]. doi:10.1038/ni.3579.
45. Mathsson L, Lampa J, Mullazehi M, Ronnelid J., Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Res Ther. 2006;8:R64. doi:10.1186/ar1926.
46. Zhao X, Okeke NL, Sharpe O, Batliwalla FM, Lee AT, Ho PP, et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther. 2008;10:R94. doi:10.1186/ar2478.
47. Van Steendam K, Tilleman K, De Ceuleneer M, De Keyser F, Elewaut D, Deforce D. Citrullinated vimentin as an important antigen in immune complexes from synovial fluid of rheumatoid arthritis patients with antibodies against citrullinated proteins. Arthritis Res Ther. 2010;12:R132. doi:10.1186/ar3070.
48. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest. 2012;122:1791–802.
49. Gonzalez SM, Payne JB, Yu F, Thiele GM, Erickson AR, Johnson PG, et al. Alveolar bone loss is associated with circulating anti-citrullinated protein antibody (ACPA) in patients with rheumatoid arthritis. J Periodontol. 2015;86:222–31.
50. Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2015;75:721–9.
51. Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384–90.